

Professor David Price has **board membership** with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; **consultancy agreements** with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; **grants and unrestricted funding for investigator-initiated studies** (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); **payment for lectures/speaking engagements** from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Skyepharma, Teva Pharmaceuticals; **payment for manuscript preparation** from Mundipharma, Teva Pharmaceuticals; **payment for the development of educational materials** from Mundipharma, Novartis; **payment for travel/accommodation/meeting expenses** from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; **funding for patient enrolment or completion of research** from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); **stock/stock options** from AKL Research and Development Ltd which produces phytopharmaceuticals; **owns** 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is **peer reviewer for grant committees** of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment.

Jaco Voorham and Arul Earnest are employed by Observational and Pragmatic research Institute and are involved in paid research in behalf of pharmaceutical organisations.

Siddesh Kamat is employed by Regeneron and the study is funded by Regeneron. Fen Ye is employed by Sanofi.